《蓝筹业绩》中生制药(01177.HK)中期基本盈利升5.2%至17.6亿人币 季度股息2港仙
中国生物制药(01177.HK)公布截至今年6月底止中期业绩,纯利12.13亿元人民币(下同),按年跌16%;基本盈利按年升5.2%至17.6亿元,每股盈利9.64分。派季度股息每股2港仙,连同已派发第一季度股息每股2港仙,首两季度合共派发股息每股4港仙。
期内营业额126.48亿元,按年升1%,新产品销售占集团总收入34.8%。按种类划分肝病用药之销售额约22.49亿元,占收入17.8%,而抗肿瘤用药收入则为40.18亿元,占收入约31.8%,骨科用药销售为10.18亿元,抗感染用药销售则为7.53亿元,呼吸系统用药销售为5.97亿元。
上半年集团研发总开支约15.41亿元,占收入约12.2%,而次季集团获得临床批件8件、生产批件6件及一致性评价获批3个、申报临床20件、一致性评价申报1个及申报生产17个。已累计有临床批件、正在进行临床试验和申报生产的在研产品共438件,其中肝病用药38件、抗肿瘤用药189件、呼吸系统用药22件、内分泌用药24件、心脑血管用药35件及其他类用药130件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.